Skip to content

Released May 9, 2023, after the close

10-Q filed May 9, 2023, 39 days after period end · 0001162194-23-000024

Q1 2023 · 10-Q
Revenue$25.12M−5.2% vs Q1 2022−7.0% vs Q4 2022
Net Income-$16.84MN/M vs Q1 2022N/M vs Q4 2022
EPS Diluted-$0.21N/M vs Q1 2022no prior Q4 2022 on file
Gross Profit$12,281,000—
Operating Income-$16,593,000N/M
Operating Cash Flow-$8,485,000N/M
Free Cash Flowderived-$9,495,000N/M
Margins · derived
Gross margin48.9%
Operating margin-66.1%+37.7 pt vs Q1 2022
Net margin-67.1%+220.8 pt vs Q1 2022

What the release said

The release

Same quarter

MetricQ1 2023Q1 2022Q1 2021Q1 2020
Revenue$25.12M$26.50M$32.79M$27.62M
Net Income-$16.84M-$76.29M-$18.82M-$15.98M
EPS Diluted-$0.21-$0.99-$0.25-$0.23

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR